Clinical Trial Update: A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

View source ↗

Summary

Postmarketing study of LEQEMBI (lecanemab) in South Korean participants with Alzheimer's disease. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

Sponsor: Eisai Korea Inc. | Conditions: Alzheimer's Disease | Status: RECRUITING